Cite
HARVARD Citation
Mauclet, C. et al. (2021). Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAFV600 mutation as an acquired resistance mechanism. Lung cancer. pp. 42-44. [Online].